292.67 USD
+2.50
0.86%
At close Apr 30, 4:00 PM EDT
After hours
292.67
+0.00
0.00%
1 day
0.86%
5 days
3.12%
1 month
5.24%
3 months
13.24%
6 months
27.54%
Year to date
30.23%
1 year
22.43%
5 years
226.42%
10 years
156.05%
 

About: Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

Employees: 46,000

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

91% more first-time investments, than exits

New positions opened: 172 | Existing positions closed: 90

30% more call options, than puts

Call options by funds: $1.2B | Put options by funds: $924M

23% more repeat investments, than reductions

Existing positions increased: 473 | Existing positions reduced: 385

5% more funds holding

Funds holding: 1,145 [Q3] → 1,203 (+58) [Q4]

1.54% more ownership

Funds ownership: 98.55% [Q3] → 100.09% (+1.54%) [Q4]

0% less capital invested

Capital invested by funds: $43.7B [Q3] → $43.5B (-$214M) [Q4]

20% less funds holding in top 10

Funds holding in top 10: 15 [Q3] → 12 (-3) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$274
6%
downside
Avg. target
$294
0%
upside
High target
$335
14%
upside

4 analyst ratings

positive
50%
neutral
50%
negative
0%
UBS
Kevin Caliendo
35% 1-year accuracy
6 / 17 met price target
14%upside
$335
Buy
Maintained
29 Apr 2025
B of A Securities
Michael Funk
50% 1-year accuracy
3 / 6 met price target
3%downside
$285
Neutral
Maintained
11 Apr 2025
Wells Fargo
Stephen Baxter
37% 1-year accuracy
11 / 30 met price target
6%downside
$274
Equal-Weight
Maintained
14 Mar 2025
Evercore ISI Group
John Belton
75% 1-year accuracy
3 / 4 met price target
4%downside
$280
Outperform
Maintained
6 Feb 2025

Financial journalist opinion

Based on 13 articles about COR published over the past 30 days

Positive
Zacks Investment Research
5 hours ago
Cencora (COR) Earnings Expected to Grow: Should You Buy?
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cencora (COR) Earnings Expected to Grow: Should You Buy?
Positive
Zacks Investment Research
1 week ago
Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year?
Here is how Cencora (COR) and Intensity Therapeutics Inc. (INTS) have performed compared to their sector so far this year.
Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year?
Positive
Zacks Investment Research
1 week ago
Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report?
Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report?
Positive
Zacks Investment Research
1 week ago
3 Undervalued Medical Device Stocks to Buy in 2025 Amid Tariff Woes
Here, we discuss three medical device stocks ,COR, HIMS and PBH, that offer cheap valuations, making them attractive bets amid tariff risks.
3 Undervalued Medical Device Stocks to Buy in 2025 Amid Tariff Woes
Positive
Zacks Investment Research
1 week ago
Why Cencora (COR) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Cencora (COR) is a Top Momentum Stock for the Long-Term
Positive
Zacks Investment Research
2 weeks ago
Here's Why You Should Add Cencora Stock to Your Portfolio Now
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why You Should Add Cencora Stock to Your Portfolio Now
Negative
Zacks Investment Research
3 weeks ago
Top 3 MedTech Stocks to Weather the Trump Tariff Turbulence
In the present market turbulence, investors may want to consider discounted stocks, such as FMS, PAHC and COR.
Top 3 MedTech Stocks to Weather the Trump Tariff Turbulence
Negative
MarketBeat
3 weeks ago
Top 3 S&P 500 Winners in a Losing Market
Fear and uncertainty have dominated the markets in 2025, with U.S. equities entering a significant correction. What began as a cautious retreat in February, sparked by policy concerns and underwhelming performance from former market leaders and Magnificent Seven stocks, like Tesla and Alphabet, has now escalated into broader selling pressure.
Top 3 S&P 500 Winners in a Losing Market
Positive
Investors Business Daily
3 weeks ago
Sellers Rule The Roost Amid Tariff Wars, But This Stock Hits A High
Cencora hit an all-time high on Friday. The post Sellers Rule The Roost Amid Tariff Wars, But This Stock Hits A High appeared first on Investor's Business Daily.
Sellers Rule The Roost Amid Tariff Wars, But This Stock Hits A High
Neutral
Zacks Investment Research
3 weeks ago
4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues
Healthcare stocks like GLID, COR, FMS and LMAT are a safe bet during times of market volatility.
4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues
Charts implemented using Lightweight Charts™